Targeted therapy for psoriasis is to target the cells as well as the molecules that induce psoriasis flare-ups, with high efficacy and improved prognosis. Psoriasis is a chronic scaly skin disease caused by a combination of heredity, immune deficiency, and environmental stimuli. Patients may appear localized red skin plaques, accompanied by silver-white scales, itching, burning and other symptoms. Psoriasis is a relatively stubborn disease, if the patient after the traditional treatment is ineffective, or when the treatment effect is poor, you can take targeted therapy. Its efficacy can remove the inflammatory factors in the body that cause psoriasis, such as tumor necrosis factor, interleukin-13, interleukin-17, and interleukin-23. The removal of inflammatory mediators can relieve disease symptoms and improve prognosis. Currently, the commonly used ones are adalimumab, etanercept, infliximab, and stuccochilizumab. It is recommended that if patients with psoriasis want to take targeted therapy, they need to combine their own situation, as well as their personal needs, and take relevant therapeutic measures under the guidance of a doctor, so as not to delay the condition.